ECOG-ACRIN

ECOG-ACRIN
Name	ECOG-ACRIN
Formation	1955 (as Eastern Cooperative Oncology Group); 2011 (consortium formation)
Headquarters	Philadelphia, Pennsylvania
Leader title	Chair
Leader name	Richard Pazdur

ECOG-ACRIN is a United States-based cancer clinical trials cooperative group that designs, conducts, and analyzes multicenter clinical trials in oncology, encompassing adult hematologic malignancies and solid tumors across academic centers, community hospitals, and international sites. It operates within a networked paradigm that includes interactions with national research agencies, professional societies, regulatory bodies, and philanthropic organizations to accelerate translation of laboratory discoveries into patient care improvements.

History

The origins trace to the formation of the Eastern Cooperative Oncology Group in the mid-20th century alongside contemporaries such as National Cancer Institute initiatives and cooperative groups including SWOG, ALLIANCE (clinical trials group), Cancer and Leukemia Group B, and Children's Oncology Group, positioning it within the postwar expansion of clinical research exemplified by collaborations like National Institutes of Health partnerships. In the early 21st century structural reforms and strategic mergers mirrored consolidation movements seen in entities like ACRIN and CALGB leading to the contemporary consortium model, paralleling reorganizations associated with Department of Health and Human Services policy shifts and Presidential Commission-level research funding debates. Historical milestones intersect with regulatory events such as approvals from the Food and Drug Administration and guideline adoptions informed by panels including the American Society of Clinical Oncology and the European Society for Medical Oncology.

Organization and governance

Governance frameworks reflect practices common to large cooperative groups involving steering committees, scientific boards, data safety monitoring boards, and executive leadership comparable to structures at Dana-Farber Cancer Institute, Mayo Clinic, Memorial Sloan Kettering Cancer Center, Johns Hopkins Hospital, and MD Anderson Cancer Center. Institutional membership spans academic medical centers like University of Pennsylvania, community networks analogous to Kaiser Permanente, and international affiliates similar to Institute Gustave Roussy and Royal Marsden Hospital. Oversight interactions include reporting relationships with federal funders such as the National Cancer Institute and policy interfacing with regulatory agencies like the Food and Drug Administration and accrediting organizations akin to Joint Commission.

Research programs and clinical trials

Research portfolios encompass randomized phase III trials, biomarker-driven phase II studies, and translational research projects that connect to basic science hubs such as Broad Institute, Cold Spring Harbor Laboratory, Salk Institute, and Fred Hutchinson Cancer Center. Trial designs employ innovations from statisticians and methodologists affiliated with institutions like Harvard T.H. Chan School of Public Health, Johns Hopkins Bloomberg School of Public Health, and University of California, San Francisco, and have contributed to practice-changing trials similar in impact to landmark studies by Stuart Orkin, James Allison, and Tasuku Honjo. Trial endpoints and data practices echo standards used by groups including ICON plc and IQVIA for data management, with safety monitoring paralleling work by the Data Safety Monitoring Board model and biostatistical oversight from centers like Fred Hutchinson.

Disease and therapeutic focus areas

The consortium conducts trials across solid tumors and hematologic malignancies, addressing diseases such as breast cancer, lung cancer, colorectal cancer, prostate cancer, pancreatic cancer, acute myeloid leukemia, non-Hodgkin lymphoma, and multiple myeloma. Therapeutic modalities studied include cytotoxic chemotherapy regimens evaluated in the tradition of investigators like Sidney Farber, targeted therapies grounded in discoveries by groups such as Genentech and Pfizer, immunotherapies following paradigms set by Bristol-Myers Squibb and Merck & Co., and radiotherapeutic combinations developed with collaborators like American Society for Radiation Oncology and European Organisation for Research and Treatment of Cancer.

Collaborations and partnerships

Partnerships extend to federal agencies including the National Cancer Institute and Centers for Medicare & Medicaid Services, academic centers such as Yale School of Medicine and Stanford University School of Medicine, industry partners like Roche and Novartis, and philanthropic funders including American Cancer Society and LIVESTRONG Foundation. International collaboration mirrors linkages seen with European Union research consortia and multinational trials coordinated with networks like Trans-Tasman Radiation Oncology Group and Asia Pacific Oncology Consortium. Data sharing and biomarker programs interact with initiatives such as The Cancer Genome Atlas, AACR Project GENIE, and repositories like dbGaP.

Funding and grants

Primary funding streams include peer-reviewed grants from the National Cancer Institute and programmatic awards administered under National Institutes of Health mechanisms, supplemented by cooperative agreements, foundation grants from organizations like Susan G. Komen, and industry-sponsored trial support from corporations including AstraZeneca and Novartis. Financial oversight and grant administration are conducted following standards used by institutions such as University of California systems and grant management offices at Columbia University, with compliance aligned to federal requirements under statutes overseen by the Office of Management and Budget.

Impact and notable outcomes

ECOG-ACRIN’s trials have contributed to regulatory approvals promulgated by the Food and Drug Administration and influenced clinical guidelines from bodies like the National Comprehensive Cancer Network and American Society of Clinical Oncology. Outcomes include practice-changing evidence in therapies for breast cancer, lung cancer, and hematologic malignancies, incorporation of biomarkers into standard care paralleling advances by The Cancer Genome Atlas teams, and generation of data used in health policy deliberations by agencies such as the Centers for Disease Control and Prevention and Centers for Medicare & Medicaid Services. Its alumni include investigators with appointments at leading centers including Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and Mayo Clinic, and its work is frequently cited alongside landmark contributions from laureates such as James P. Allison and Tasuku Honjo.

Category:Cancer research organizations